Company Profile
Nanobiotix Stock Price, News & Catalysts
- Ticker:
- NBTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- France and listed in the U
Stock performance
27.32 USD (+1.54%)
Close
Last updated: November 19, 2026
1.86B USD
Market cap
Why the stock is moving
As of Nov 19, 2026, NBTX closed up 1.54% at $27.32. No new same-company headline was identified in the current news window.
Company overview
Physics-Based Nanotherapeutics Company
Nanobiotix develops nanoparticle-based therapies intended to enhance the effects of established cancer treatments. Its lead program uses a physical interaction with radiotherapy rather than a tumor-specific biological target.
JNJ-1900 Radioenhancer
JNJ-1900, formerly NBTXR3, consists of functionalized hafnium oxide nanoparticles administered through a one-time intratumoral injection. When exposed to radiotherapy, the particles increase localized energy deposition and are designed to produce greater tumor-cell destruction.
Local and Immune Effects
In addition to amplifying radiation inside the injected tumor, JNJ-1900 is being studied for its potential to trigger adaptive immune responses and antitumor activity beyond the treated site. This mechanism supports evaluation with radiotherapy alone and in combinations with immunotherapy.
Johnson & Johnson Partnership
Johnson & Johnson holds global development and commercialization rights to JNJ-1900 under a licensing agreement. Nanobiotix supplies product and remains economically exposed through milestones and royalties while Johnson & Johnson leads major global studies.
Multi-Tumor Clinical Program
The program includes the Phase 3 NANORAY-312 study in locally advanced head and neck cancer, the LUMIRAY Phase 1b study in head and neck cancer, and the Phase 2 CONVERGE study in unresectable stage III non-small cell lung cancer.
Next-Generation Nanoprimer Research
Nanobiotix is also working on Nanoprimer technologies intended to use nanoparticles to modulate the tumor microenvironment and enhance systemic cancer therapies. These programs provide a longer-term platform opportunity beyond radioenhancement.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nanobiotix (NBTX)?
Nanobiotix (NBTX) most recently closed at 27.32 USD, a +1.54% move versus the previous session.
What is the market cap of Nanobiotix (NBTX)?
Nanobiotix currently has a market capitalization of 1.86B USD on BioPharmSignal.
What does Nanobiotix do?
Physics-Based Nanotherapeutics Company Nanobiotix develops nanoparticle-based therapies intended to enhance the effects of established cancer treatments. Its lead program uses a physical interaction with radiotherapy rather than a tumor-specific biological target. JNJ-1900 Radioenhancer JNJ-1900, formerly NBTXR3, consists of functionalized hafnium oxide...
On which exchange is NBTX stock listed?
Nanobiotix (NBTX) is associated with NASDAQ, France and listed in the U, Biopharma.
What is JNJ-1900?
JNJ-1900 Radioenhancer JNJ-1900, formerly NBTXR3, consists of functionalized hafnium oxide nanoparticles administered through a one-time intratumoral injection.
Which conditions is Nanobiotix targeting with JNJ-1900?
Nanobiotix is associated with cancer therapeutics based on its company overview and current catalyst commentary.
What is NANORAY-312?
Multi-Tumor Clinical Program The program includes the Phase 3 NANORAY-312 study in locally advanced head and neck cancer, the LUMIRAY Phase 1b study in head and neck cancer, and the Phase 2 CONVERGE study in unresectable stage III non-small cell lung cancer.
What is Physics-Based?
Physics-Based Nanotherapeutics Company Nanobiotix develops nanoparticle-based therapies intended to enhance the effects of established cancer treatments.
